Literature DB >> 24282055

Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma.

Benjamin Yip1, James M Wantuck, Lily H Kim, Robert J Wong, Aijaz Ahmed, Gabriel Garcia, Mindie H Nguyen.   

Abstract

BACKGROUND AND AIM: Hepatitis C virus (HCV) is an important cause of hepatocellular carcinoma (HCC) in Asians; however, it is often overlooked due to the high prevalence of hepatitis B virus in Asians. This study examines HCV-related HCC in Asians.
METHODS: We conducted a retrospective cohort study of 792 consecutive Asian (n = 220) and non-Asian (n = 572) patients with HCV-related HCC identified at Stanford University Medical Center using International Classification of Diseases-9 diagnosis between July 1996 and June 2012.
RESULTS: Asian patients were much older [66 (38-88) vs. 56 (31-87) years, P < 0.0001] and more likely to be female (33 vs. 19 %, P < 0.0001). A larger proportion of Asians were diagnosed with HCC within 2 years of HCV diagnosis (35 vs. 20 %, P = 0.001). Asian patients were more likely to undergo palliative therapy (46 vs. 28 %) and less likely to be listed for liver transplantation (20 vs. 48 %, P < 0.001), despite similar rates of meeting Milan criteria (52 vs. 58 %, P = 0.16). Overall, there was a trend for higher median survival rates in Asians (30 vs. 21 months, P = 0.091). Asians had higher long-term survival with palliative therapy only (5-year survival: 28 vs. 10 %, P < 0.0001); however, survival was similar among patients listed for liver transplantation.
CONCLUSIONS: There were distinct differences in clinical presentations of Asian and non-Asian patients with HCV-related HCC. Asians with HCV-related HCC are less likely to undergo liver transplantation and more likely to have delayed HCV diagnosis. Improved strategies in HCV screening in Asians are needed, as it may lead to earlier diagnosis and treatment of HCV infection and possible prevention of HCC development.

Entities:  

Mesh:

Year:  2013        PMID: 24282055     DOI: 10.1007/s10620-013-2948-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians in Hawaii.

Authors:  Margaret Ochner; Linda L Wong; Kristal Wimmer-Kunitomo
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

2.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

3.  Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type.

Authors:  Yulia Zak; Kim F Rhoads; Brendan C Visser
Journal:  Arch Surg       Date:  2011-03-21

4.  Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans.

Authors:  Nghia H Nguyen; Philip Vutien; Huy N Trinh; Ruel T Garcia; Long H Nguyen; Huy A Nguyen; Khanh K Nguyen; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2010-04-09       Impact factor: 6.047

Review 5.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

8.  Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic.

Authors:  Myron J Tong; Hai-En Sun; Carlos Hsien; David S K Lu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

Review 9.  Systematic review: Asian patients with chronic hepatitis C infection.

Authors:  L H Nguyen; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2013-04-05       Impact factor: 8.171

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  13 in total

1.  HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.

Authors:  Mei-Hsuan Lee; Tiffany I Hsiao; Shreenidhi R Subramaniam; An K Le; Vinh D Vu; Huy N Trinh; Jian Zhang; Mingjuan Jin; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Mindie H Nguyen
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

2.  The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules.

Authors:  Linh Truong; John Tat; Molly Booy; Annie Le; Jeanne Marie Marasigan; Christine Yuan; Athena Zeng; Anand Panchal; Georgia Robins Sadler
Journal:  J Cancer Educ       Date:  2016-06       Impact factor: 2.037

Review 3.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

4.  Effect of hepatitis C virus infection on the outcomes of in vitro fertilization.

Authors:  Lin Yang; Ronghua Zhao; Yingjie Zheng; Xueru Song
Journal:  Int J Clin Exp Med       Date:  2015-04-15

5.  Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention.

Authors:  Anne C Moorman; Jian Xing; Stephen Ko; Loralee B Rupp; Fujie Xu; Stuart C Gordon; Mei Lu; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Vinutha Vijayadeva; Mark A Schmidt; Scott D Holmberg
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

6.  HCV Prevalence in Asian Americans in California.

Authors:  Oliver N Lin; Christine Chang; Joyce Lee; Ailinh Do; Marina Martin; Andy Martin; Mindie H Nguyen
Journal:  J Immigr Minor Health       Date:  2017-02

7.  Family First: Asian Americans' Attitudes and Behaviors Toward Deceased Organ Donation.

Authors:  Laura A Siminoff; Susan Bolt; Heather M Gardiner; Gerard P Alolod
Journal:  J Racial Ethn Health Disparities       Date:  2019-09-06

8.  Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Jiang Chen; Jie Zhao; Rui Ma; Hui Lin; Xiao Liang; Xiujun Cai
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

9.  Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study.

Authors:  Maya R Ladenheim; Nathan G Kim; Pauline Nguyen; An Le; Marcia L Stefanick; Gabriel Garcia; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2016-07-25

10.  Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.

Authors:  Xinhua Zou; Wenzhe Fan; Miao Xue; Jiaping Li
Journal:  Cancer Manag Res       Date:  2021-05-18       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.